# Cannabinoids for Children: Medical Evidence Reviewed > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-for-children-medical-evidence/ > **Published:** 2026-03-12T21:22:39-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:59:09-04:00 > **Clinical Summary:** Explore cannabinoids for children medical evidence, focusing on safety and efficacy in pediatric conditions like treatment-resistant epilepsy. --- #### Clinical Takeaway Cannabinoids have been studied across a wide range of pediatric medical conditions, with the current evidence base drawing from hundreds of studies including clinical trials and observational data. The strongest and most consistent findings support the use of pharmaceutical cannabinoids, particularly for treatment-resistant epilepsy. Parents and clinicians considering [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) for children should rely on formally studied preparations and work closely with a knowledgeable physician, as safety and efficacy data vary significantly by condition and formulation. ### #2 Cannabinoids for Medical Purposes in Children: A Living Systematic Review. **Citation:** Chhabra Manik et al. *Cannabinoids for Medical Purposes in Children: A Living Systematic Review.* Acta paediatrica (Oslo, Norway: 1992). 2025. PMID: 40437694. **Study type:** Journal Article, Systematic Review  |  **Topic area:** Autism  |  **CED Score:** 13 Design: 5 Journal: 0 N: 2 Recency: 2 Pop: 3 Human: 1 Risk: 0 Why This Matters This living systematic review addresses a critical evidence gap by systematically synthesizing safety and efficacy data on cannabinoid use in pediatric populations, where clinical evidence remains sparse and prescribing practices often outpace rigorous study. The continuous update mechanism ensures clinicians have access to emerging evidence as new trials are published, enabling more informed decision-making regarding cannabinoid therapy in children with treatment-resistant conditions. By cataloging both benefits and adverse events across pediatric indications, this review provides the evidence foundation necessary to establish appropriate clinical guidelines and safety protocols for an increasingly utilized but understudied therapeutic class in vulnerable populations. **Methodological Considerations:** - Small sample — underpowered for subgroup analysis **Abstract:** AIM: We developed a living systematic review (LSR) that will continuously map the safety and reported benefit data related to cannabinoid use for medical purposes in children. METHODS: MEDLINE, Embase, PsycInfo, and the Cochrane Library were searched from inception to April 2023. Studies involving at least one child  20% studies) in studies enrolling children were somnolence, diarrhoea, vomiting, and decreased appetite. CONCLUSION: These findings will continue to be updated to inform practice and reveal knowledge gaps for future research. Clinical Perspective This living systematic review represents a necessary effort to synthesize the scattered evidence on pediatric cannabinoid use, yet practitioners should approach the emerging data with appropriate caution given the heterogeneity of study designs, populations, and outcome measures typically found in this literature. The review’s strength lies in its continuous updating mechanism, which acknowledges that [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) is evolving rapidly, but this also means firm conclusions remain elusive for most pediatric indications outside of severe, treatment-resistant epilepsy where evidence is most robust. Critical confounders include variable cannabinoid formulations and ratios, inconsistent dosing protocols, difficulty blinding participants, and the challenge of separating placebo effects from true pharmacological benefit in conditions like chronic pain or anxiety. Clinicians should view this synthesis as a foundation for informed discussions with families about the limited evidence base, the genuine unknown risks of cannabinoids during critical neurodevelopmental windows, and the importance of reserving use for compelling indications where conventional options have failed, while documenting outcomes  |   |  Further Reading Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 12, 2026](https://cedclinic.com/cannabis-regulatory-updates-march-2026/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40437694/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336964/)[DOI ↗](https://doi.org/10.1111/apa.70140) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoids for Pediatric Care: Evidence-Based Clinical Review](https://cedclinic.com/living-systematic-review-cannabinoids-pediatric-evidence/) A comprehensive clinical review of cannabinoids in pediatric care, summarizing current evidence and clinical applications. [Read Clinical Review](https://cedclinic.com/living-systematic-review-cannabinoids-pediatric-evidence/) [Cannabinoids in Pediatric Medicine: Evidence-Based Care and Emerging Research](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) Explore emerging research and evidence-based care practices for cannabinoids in pediatric medicine. [Explore Emerging Research](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) [Cannabis Medicine in Pediatrics: Evidence-Based Care and Emerging Research](https://cedclinic.com/cannabinoids-pediatric-safety-evidence-based-care/) An evidence-based overview of [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) in pediatrics, highlighting [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and therapeutic potential. [Discover More](https://cedclinic.com/cannabinoids-pediatric-safety-evidence-based-care/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoids%20for%20Children%3A%20Medical%20Evidence%20Reviewed&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-for-children-medical-evidence%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-for-children-medical-evidence%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoids%20for%20Children%3A%20Medical%20Evidence%20Reviewed%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-for-children-medical-evidence%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).